Veristat, TRI partner to improve clinical trial compliance and risk monitoring

By Maggie Lynch

- Last updated on GMT

(Image: Getty/ Denis Isakov)
(Image: Getty/ Denis Isakov)

Related tags CRO GCP Fda risk assessment Risk Software

The MA-based CRO Veristat is partnering with Triumph Research Intelligence to provide centralized and risk-based monitoring solutions to improve clinical trial compliance.

Per the partnership, Triumph Research Intelligence (TRI) will provide risk-based monitoring (RBM) services to the contract research organization (CRO) Veristat.

TRI’s RBM platform, OPRA, improves data reliability, patient safety, and operational efficiency, according to the company.

A spokesperson for TRI told us that OPRA is a cloud-based solution designed for RBM specifically. It uses data from multiple sources and employs statistical algorithms and data visualization to provide insights to the centralized monitoring team.

“Based on the efficacy of the risk detection and management, the approach can be adjusted as the trial progresses to ensure an optimal approach to quality management at all times,”​ the TRI spokesperson explained.

A spokesperson for Veristat said that by providing these services to its clients it can provide support to optimize clinical trial data quality from “the very start of their trial.”

This technology allows sponsors to quickly identify areas of quality risk and allows CROs like Veristat to target onsite-monitoring activities.

“Just identifying risks isn’t sufficient. Proactively managing those risks through improvement activities, and recording and monitoring whether corrective activities are effective, is key to demonstrating trial safety and efficacy,”​ said Veristat’s spokesperson.

According to Veristsat, through this type of risk monitoring, data quality assurance is built right into the trial. The company also said that the partnership ensures compliance through creating bespoke key risk indicators (KRI’s) and key performance indicators (KPIs) that are specific to each trial. This technology will ensure regulatory compliance and improve patient safety, according to the company.

ICH GCP E6(R2)

 Since the US Food and Drug Administration (FDA) issued the International Council for Harmonization’s​ (ICH) Guideline for Good Clinical Practice​ (GCP), otherwise known as ICH GCP E6(R2)​, clinical trial design compliance has been an important consideration. Under these specifications management and oversight, patient safety, data integrity, and computer system validation must meet the guidelines laid out as a way to improve efficacy and efficiency.

ICH GCP encourages the adoption of risk-based practices in clinical trials.

“It’s important to note that compliance with the ICH GCP lies with both the sponsor and with Veristat,” ​said the Veristat spokesperson, adding, “With RBM, through the collection of relevant metrics, appropriate data-driven decision can be made which can help to drive safety and better quality data.”

Related news

Show more

Related products

show more

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Products

View more

Webinars